Unraveling cocaine metabolism in patients with cocaine use disorder for the purpose of potentially improving bioanalytical tests for cocaine use - Unraveling cocaine metabolism in patients with CUD

Start Date16 Sep 2024

Sponsor / Collaborator-

NCT06443255 / CompletedPhase 3IIT

Comparison of Cocaine, Lidocaine/xylometazoline and Saline for Intranasal Analgesia - a Blinded Triple Crossover Study

When performed by trained personnel nasotracheal intubation is a safe and effective technique for attaining a secure airway in preparation for surgery of the head and neck. The procedure can be deemed necessary due to the nature of the surgical procedure or considerations in regard to the patient's comorbidities. For a certain group of patients with expected difficult airways, the procedure is done whilst they are awake and aided by fiberoptics.
For these awake patients, extra precautions must be taken to ensure the procedure is conducted with minimal pain and discomfort. The pain and discomfort arises from the mechanical manipulation of the nasal mucosa and can be alleviated in part by means of topical analgesia as well as through decongestion, providing more space within the nasal cavity. For these purposes, several drugs in varying combinations and dosages are used, but no single drug choice is universally recommended.
Cocaine is one of these appropriate drugs. It is a magistral formula used especially due to its unique combination of both vasoconstrictive and analgesic properties. Concerns have though been raised regarding cocaine's potential toxicity and alternative medications are continuously sought after.
A combination of lidocaine and xylometazoline can also be used for preparation of the nose prior to awake nasal fiberoptic intubation. Lidocaine contributes with its analgesic effect whilst xylometazoline functions as the vasoconstrictor.
The investigators wish to compare the analgesic effects of cocaine and lidocaine/phenylephrine to each other and saline when subjectively scored on a visual analogue scale of 0-100 mm immediately after simulated awake nasal intubation on healthy volunteers.

Start Date01 Jul 2024

Sponsor / Collaborator

Rigshospitalet

NCT05809453 / CompletedPhase 1/2IIT

Intranasal Cocaine and Temperature Regulation During Exercise

Assess the effects of intranasal cocaine on temperature regulation and whole-body sweat rate during exercise in warm environmental conditions.

Start Date01 Sep 2023

Sponsor / Collaborator

The University of Texas Southwestern Medical Center

100 Clinical Results associated with Cocaine Hydrochloride

100 Translational Medicine associated with Cocaine Hydrochloride

100 Patents (Medical) associated with Cocaine Hydrochloride

36,991

Literatures (Medical) associated with Cocaine Hydrochloride

01 Jan 2025·Progress in Neuro-Psychopharmacology and Biological Psychiatry

Brain structural differences in cocaine use disorder: Insights from multivariate and neurotransmitter analyses

Article

Author: Klugah-Brown, Benjamin ; Biswal, Bharat B. ; Yang, Zhenzhen ; Zhou, Wenchao ; Biswal, Bharat B ; Ding, Guobin

Cocaine use disorder (CUD) is a chronic and relapsing neuropsychiatric disorder characterized by structural and functional brain lesions, posing a significant public health challenge. While the disruptive effects of cocaine on neurotransmitter systems (receptors/transporters) have been well established, the patterns of brain structural abnormalities in CUD and its interaction with other factors remain an ongoing topic of investigation. We employed source-based morphometry (SBM), a multivariate approach on 50 CUD participants and 50 matched healthy controls from the public SUDMEX CONN dataset. This method allowed us to identify co-varying patterns of brain tissue volume differences, and further explore the effect of average cocaine dosage through moderation analysis. Spatial correlation analysis was also performed to examine micro-macro structural consistency between tissue volume variations and chemoarchitectural distribution of dopamine and serotonin. Our SBM analysis findings were consistent with reward-related neuroadaptations in the striato-thalamo-cortical and limbic pathways and also exhibited co-localization with the distribution of dopamine and serotonin systems. The moderation analysis suggested that the average dosage positively strengthens cocaine consumption years' effect on brain structures. By integrating our findings of gray and white matter volume differences and corresponding neurotransmitter profiles, this comprehensive view not only strengthens our understanding of the brain's structural abnormalities in CUD, but also reveals potential mechanisms underlying its development and progression.

01 Jan 2025·Journal of Substance Use and Addiction Treatment

Improvement in coping skills from culturally-adapted digital CBT for Spanish-speaking Hispanics with substance use disorder: Secondary analysis of a randomized clinical trial

Article

Author: Frankforter, Tami ; Paris, Manuel ; Loya, Jennifer M ; Muro-Rodriguez, Nancy J. ; Kiluk, Brian D ; Rojas Perez, Oscar F ; Nich, Charla ; Rojas Perez, Oscar F. ; Kiluk, Brian D. ; Jaramillo, Yudilyn ; Muro-Rodriguez, Nancy J ; Loya, Jennifer M. ; Benitez, Bryan

INTRODUCTIONDeveloping adaptive coping skills for avoiding substance use is a proposed treatment mechanism of cognitive behavioral therapy (CBT) for substance use disorder (SUD). However, the generalizability of research on treatment mechanisms of CBT for SUD is limited by the underrepresentation of racial/ethnic minorities in clinical trials. In a secondary analysis of clinical trial data, we tested whether a culturally-adapted digital CBT program for Hispanics ("Spanish CBT4CBT") improved the quality of coping skills for avoiding substance use. We also tested whether coping skills' quality was associated with reductions in primary substance use.METHODSParticipants were Spanish-speaking Hispanic adults seeking outpatient treatment for SUD (n = 85; 68 % male; primary substance type: 36 % cannabis, 33 % alcohol, 26 % cocaine, 5 % other). They were randomized to 8 weeks of outpatient treatment as usual (TAU) or TAU + Spanish CBT4CBT and assessed for 6 months after treatment. The study conducted separate analyses for the full sample (n = 85) and for those who engaged in at least 5 treatment sessions ("treatment exposed"; n = 64). Daily substance use and coping skills' quality were assessed repeatedly during the treatment and follow-up periods. Bayesian mixed models for repeated measures tested hypotheses.RESULTSAmong treatment-exposed participants, those receiving TAU + Spanish CBT4CBT improved the quality of coping skills more than TAU alone during the treatment period (b = 0.77; 95 % CI[0.08, 1.47]), but this difference was not detected during the follow-up period. In the full sample and treatment exposed subsample, participants with higher quality coping skills during the study reported less primary substance use (b = -0.67; 95 % CI[-1.08, -0.26]). Among treatment-exposed participants only, within-person increases in the quality of coping skills were associated with reductions in future primary substance use (b = -0.18; 95 % CI[-0.36, -0.01]).CONCLUSIONSSpanish-speaking Hispanics with SUD may improve the quality of their coping skills more when they are sufficiently exposed to a culturally-adapted digital CBT program during outpatient treatment. Coping skills' quality may be a mechanism of CBT for SUD among Hispanic populations. Spanish-speaking Hispanics' access to treatments that target mechanisms of behavior change may be expanded by digital therapeutics.

01 Jan 2025·Progress in Neuro-Psychopharmacology and Biological Psychiatry

Sequential physical and cognitive training disrupts cocaine-context associations via multi-level stimulation of adult hippocampal neurogenesis

Article

Author: de Guevara-Miranda, David Ladrón ; Mañas-Padilla, M. Carmen ; Mañas-Padilla, M Carmen ; Pérez-Cano, Ana M. ; Pérez-Berlanga, José Manuel ; Pérez-Cano, Ana M ; Ávila-Gámiz, Fabiola ; Gil-Rodríguez, Sara ; Santín, Luis J. ; Santín, Luis J ; Zambrana-Infantes, Emma Noelia ; Zambrana-Infantes, Emma N ; Tronel, Sophie ; Ladrón de Guevara-Miranda, David

Cocaine-related contextual cues are a recurrent source of craving and relapse. Extinction of cue-driven cocaine seeking remains a clinical challenge, and the search for adjuvants is ongoing. In this regard, combining physical and cognitive training is emerging as a promising strategy that has shown synergistic benefits on brain structure and function, including enhancement of adult hippocampal neurogenesis (AHN), which has been recently linked to reduced maintenance of maladaptive drug seeking. Here, we examined whether this behavioral approach disrupts cocaine-context associations via improved AHN. To this aim, C57BL/6J mice (N = 37) developed a cocaine-induced conditioned place preference (CPP) and underwent interventions consisting of exercise and/or spatial working memory training. Bromodeoxyuridine (BrdU) was administered during early running sessions to tag a subset of new dentate granule cells (DGCs) reaching a critical window of survival during spatial learning. Once these DGCs became functionally mature (∼ 6 weeks-old), mice received extinction training before testing CPP extinction and reinstatement. We found that single and combined treatments accelerated CPP extinction and prevented reinstatement induced by a low cocaine priming (2 mg/kg). Remarkably, the dual-intervention mice showed a significant decrease of CPP after extinction relative to untreated animals. Moreover, combining the two strategies led to increased number and functional integration of BrdU⁺ DGCs, which in turn maximized the effect of spatial training (but not exercise) to reduce CPP persistence. Together, our findings suggests that sequencing physical and cognitive training may redound to decreased maintenance of cocaine-context associations, with multi-level stimulation of AHN as a potential underlying mechanism.

181

News (Medical) associated with Cocaine Hydrochloride

24 Oct 2024

·www.prnewswire.com

Montana: A Trailblazer in Eliminating Regulatory Barriers for Opioid Use Disorder Treatment, According to Community Medical Services

HELENA, Mont., Oct. 24, 2024 /PRNewswire/ -- When the Substance Abuse and Mental Health Services Administration (SAMHSA) updated their recommendations governing Opioid Treatment Programs (OTPs) in April 2024, Montana was among the first to implement significant changes for OTPs in the state. Community Medical Services (CMS) currently provides care to Montana residents at 4 clinics, (Billings, Bozeman, Kalispell and Missoula), and has been working to adjust their clinical guidance to institute these changes aimed at improving patient safety and retention in treatment programs. This is a crucial step forward in addressing the opioid epidemic, providing more effective care for individuals struggling with opioid use disorder. Extended Take-Home Doses Under the new rules, patients are no longer required to come to a clinic at the same frequency as they have historically needed to. Medical providers can determine the appropriate number of take-home doses based on individual patient needs and criteria, including: Absence of active substance use disorders or other health conditions that increase the risk of patient harm Regular attendance for supervised medication administration Absence of serious behavioral problems Absence of known recent diversion activity Safe transportation and storage of take-home medication Higher Initial Dosing The initial dose of methadone, which was historically capped on the first day, can now be titrated more quickly at the medical provider's discretion, allowing patients with higher opioid tolerance to get to a therapeutic dose more quickly. This change acknowledges the varying levels of opioid tolerance among patients, exacerbated by the increased presence of fentanyl in the illicit drug supply, and enables medical providers to tailor treatment to individual needs. Drug Screens The presence of unprescribed amphetamine or cocaine on drug screen results will no longer be the sole limiting factor to requiring patients to not have to come into clinics daily, unless it increases the risk of overdose. This change recognizes that patients with opioid use disorder may also struggle with other substance use disorders and requires medical providers to assess each patient's unique situation. Conclusion The SAMHSA Final Rule changes mark a crucial step forward in enhancing Opioid Treatment Programs in Montana. By providing more flexible and individualized treatment options, these changes aim to improve patient safety and retention, decrease daily patient volumes at clinics, and ultimately support individuals in their journey towards recovery. How CMS is Implementing SAMHSA's Changes At its 4 clinics in Montana, CMS has proactively implemented the SAMHSA Final Rule changes. Our approach focuses on balancing patient safety with reducing barriers to treatment, ensuring that any changes benefit our patients and their recovery outcomes. Triweekly dosing—allowing patients to come to the clinic only three times per week—has become the new standard. This means that most patients, even those who might test positive for stimulants or miss some clinic days, are not required to visit the clinic more than three times a week. For patients who meet certain stability criteria, the option to advance to weekly clinic visits is available after just two weeks of triweekly dosing. This provides immense relief to patients who previously struggled to balance daily trips to the clinic with their other responsibilities, such as work or family. Visit the CMS blog on our website for a complete review by our Chief Science Officer, Dr. Robert Sherrick, of how we are taking an active step toward implementing these changes and seeing early positive results Media Contact: John Koch- Director Public Relations [email protected] 2827 Fort Missoula Rd, Missoula, MT 59804 8707 Jackrabbit Ln Suite D, Belgrade, MT 59714 2415 S Catlin St, Missoula, MT 59801 795 Sunset Blvd F, Kalispell, MT 59901 2040 Rosebud Dr, Billings, MT 59102 2827 Fort Missoula Rd, Missoula, MT 59804 SOURCE Community Medical Services WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

24 Oct 2024

·www.biospace.com

New Study Reveals Unprecedented Increases in Fentanyl and Stimulant Concentrations in Urine Drug Test Results

SAN DIEGO--(BUSINESS WIRE)--A study published in JAMA Network Open , led by Andrew Huhn, PhD, MBA, Associate Professor of Psychiatry and Behavioral Sciences at Johns Hopkins University School of Medicine, Kelly Dunn, PhD, MBA, Professor of Psychiatry and Behavioral Sciences at Johns Hopkins University School of Medicine, and co-authored by Millennium Health researchers, illustrates striking increases in the amounts of illicit fentanyl, methamphetamine, and cocaine detected in urine drug testing (UDT) specimens since 2013. The analysis showed that the concentrations of fentanyl and methamphetamine were 8.3 and 5.2 times higher, respectively, in 2023 compared to 2013 (Figure). Cocaine concentrations also doubled across this time period, whereas those for heroin fell by more than half. The JAMA Network Open article can be accessed here . “Fentanyl, methamphetamine, and cocaine concentrations are higher now relative to any time in the past decade, suggesting that the people who are using these drugs are doing so in larger quantities and/or with greater frequency now,” said Huhn. “The findings also demonstrate that aggregated, quantitative UDT data offer a scalable surveillance method that can provide swift and nimble feedback on real-time changes in drug exposure levels as well as emerging threats, like xylazine, that are not routinely captured by other methods,” he added. The analysis of 921,931 unique patient UDT specimens collected in substance use disorder treatment settings across the U.S. also evaluated how these concentrations have changed in different parts of the country. With a few exceptions (e.g., greater methamphetamine concentrations in the West and part of the South, largely stable heroin concentrations in the West), changes in drug exposure concentrations have been relatively similar across the U.S. over time. “These findings reveal that the drug use epidemic is evolving not only in terms of what drugs are being used but how much drug is being used ,” said Millennium Health Chief Clinical Officer Angela Huskey, PharmD, CPE. “This is the most granular assessment of drug use patterns in the U.S. to date and highlights an important, underappreciated nuance about drug use that may affect overdose risk and other clinically relevant phenomena.” About Millennium Health Millennium Health is an accredited specialty laboratory with over 15 years of experience in drug testing . We provide objective information about patients’ recent use of prescription medications and/or illicit drugs which helps clinicians monitor and treat millions of Americans living with chronic pain, substance use disorders, mental health disorders or other health conditions. Our ability to monitor drug use trends allows us to alert clinicians, health agencies and others to real-time drug use changes to help inform more targeted drug overdose prevention and response strategies to save lives. Contacts MEDIA CONTACT: Jody Schneider Millennium Health Jody.Schneider@millenniumhealth.com 619-917-6810

Clinical Study

01 Oct 2024

·www.prnewswire.com

AI-Driven Market Transformation, Europe's Pharma E-Commerce to Grow by USD 38.7 Billion from 2024-2028, Boosted by Internet Accessibility

NEW YORK, Oct. 1, 2024 /PRNewswire/ -- Report with the AI impact on market trends- The global pharma e-commerce market in Europe size is estimated to grow by USD 38.7 billion from 2024-2028, according to Technavio. The market is estimated to grow at a CAGR of almost 16.27% during the forecast period. Availability of internet provides convenience to consumers is driving market growth, with a trend towards growing acceptance in newly regulated european states. However, illegal and counterfeit trading of drugs through e-pharmacy poses a challenge. Key market players include Ace Chemist Direct, apo rot GmbH, Apotea AB, Arzneiprivat, Atropa Pharmacy, Chemist4U Innox Trading Ltd., Dirk Rossmann GmbH, DocMorris AG, EURO PHARM International Canada Inc., Farmacia Campoamor, Juvalis, McKesson Corp., myCARE e.k, Parafarmacia online, Pharmacy2U Ltd., Redcare Pharmacy, The French Pharmacy, UK MEDS Direct Ltd., Walgreens Boots Alliance Inc., and Wort and Bild Verlag Konradshohe GmbH and Co. KG. Continue Reading Technavio has announced its latest market research report titled pharma e-commerce market in Europe 2024-2028 Key insights into market evolution with AI-powered analysis. Explore trends, segmentation, and growth drivers- View the snapshot of this report Market Driver Pharma e-commerce in Europe is witnessing significant growth due to the increasing demand for personalized medicine and health solutions. Leveraging data analytics and artificial intelligence, these platforms provide customized recommendations, treatment plans, and wellness programs based on individual preferences and health histories. Personalized medicine, which involves customizing medical treatment to each patient's unique characteristics, is facilitated through a wide range of offerings, including specialty drugs and compounded medications. Patients can work with healthcare professionals to develop personalized treatment regimens and order necessary medications online. The trend extends beyond disease treatment to encompass wellness and preventive care, with e-commerce platforms offering health supplements, vitamins, and wellness products tailored to individual health goals. The European pharma e-commerce market is expected to grow, fueled by this trend and the innovation it inspires, including genetic testing services and health monitoring devices. The European pharma e-commerce market is experiencing significant growth, with medications, medical supplies, and healthcare products leading the way. Remote healthcare services, such as telemedicine and e-prescriptions, are also trending, especially among the elderly population with chronic diseases. Consumer convenience and cost-effective solutions are key drivers, with many opting for online pharmacies and mail-order services. However, challenges persist, including counterfeit pharmaceuticals, data protection, and consumer trust. Healthcare systems and internet connectivity are essential for the success of digital healthcare solutions. Omnichannel retailing, including inventory data and logistics, is crucial for supply chain efficiency. Direct sales to healthcare professionals are also increasing. E-prescriptions and digital prescription services are becoming more common, but illegal and unregulated online pharmacies pose a threat to consumer safety. Quality assurance and regulatory compliance are essential to maintain consumer trust. Request Sample of our comprehensive report now to stay ahead in the AI-driven market evolution! Market Challenges The proliferation of counterfeit drugs in the European pharma e-commerce market poses a significant challenge. These drugs, sold through virtual platforms, undermine industry integrity and pose health risks due to incorrect ingredients or dosages. Illicit drugs such as cannabis, heroin, and cocaine are commonly traded. This globalized counterfeit drug trade increases societal threats, including drug-related crimes and fatalities from overdoses. E-commerce's lack of regulation and oversight enables third-party sellers to exploit loopholes, making it difficult for authorities to monitor and control sales effectively. This situation negatively impacts the growth of the pharma e-commerce market in Europe, potentially hindering its forecasted expansion. The European pharma e-commerce market is experiencing significant growth due to an aging population and the rise of online and mail-order pharmacies. Challenges include managing chronic diseases, ensuring patient safety, and addressing illegal and unregulated online pharmacies. Digital prescription services and e-prescriptions are key trends, but logistics and inventory data management are crucial for success. Omnichannel retailing, including OTC medications and prescription medications, targets a large patient population. Health insurers and digital healthcare platforms are driving demand for electronic prescriptions and mobile applications. AI chatbots and machine learning enable personalized patient care, while data analytics and prescription refills enhance convenience. Cross-border e-commerce and drug counterfeiting pose risks, requiring strict regulation and biometric identification for security. The diabetes segment and immune-system diseases are major growth areas in the B2C market. Manufacturer-owned marketplaces and digital technologies are transforming the industry, offering new opportunities for growth. Discover how AI is revolutionizing market trends- Get your access now! Segment Overview This pharma e-commerce market in Europe report extensively covers market segmentation by Product 1.1 Medications 1.2 Health/wellness and nutrition 1.3 Personal care and essentials Type 2.1 Rx 2.2 OTC Geography 3.1 Europe 1.1 Medications- The European pharma e-commerce market is experiencing significant growth due to the increasing demand for medications as the population ages and the prevalence of chronic diseases rises. Online pharmacies offer consumers the convenience of purchasing essential medications without visiting physical pharmacies, making it an attractive option for individuals with mobility issues, busy lifestyles, or those living in remote areas. These platforms provide access to a wide range of medications, including specialty drugs and rare medications, ensuring consumers have access to the necessary treatments regardless of their location. Additionally, online platforms offer valuable information on medication side effects, low-cost substitutes, and potential drug interactions, enabling consumers to make informed purchasing decisions. These factors contribute to the anticipated growth of the medications segment and the pharma e-commerce market in Europe during the forecast period. Download a Sample of our comprehensive report today to discover how AI-driven innovations are reshaping competitive dynamics Research Analysis Pharma e-commerce in Europe is experiencing significant growth, driven by the increasing elderly population and the demand for convenient healthcare solutions. Online pharmacies and mail-order pharmacies are becoming popular, offering prescription medications, over-the-counter pharmaceuticals, and healthcare products. Telemedicine and digital prescription services enable remote healthcare consultations and electronic prescriptions. However, the rise of illegal online pharmacies poses a threat, selling counterfeit pharmaceuticals and compromising data protection. Two-factor authentication and data analytics help ensure security and personalized services. Mobile applications facilitate prescription refills and remote healthcare services. Artificial intelligence and data analytics improve patient care and optimize supply chain management. Overall, pharma e-commerce in Europe offers a wide range of digital platforms for medications, medical supplies, and healthcare products, enhancing consumer convenience and accessibility for chronic disease management and life expectancy improvement. Market Research Overview The Pharma E-Commerce Market in Europe is experiencing significant growth due to the increasing elderly population, chronic diseases, and advancements in digital healthcare. Online pharmacies and mail-order pharmacies are becoming increasingly popular, offering convenience and accessibility to patients. Telemedicine and e-prescriptions are also on the rise, enabling remote healthcare services and digital prescription services. However, the market also faces challenges such as illegal and unregulated online pharmacies, drug counterfeiting, and healthcare accessibility issues. Healthcare professionals, health insurers, and manufacturer-owned marketplaces are also playing key roles in this evolving landscape. Omnichannel retailing, inventory data management, logistics, and cost-effective solutions are essential for success in this market. Digital technologies, including AI chatbots, machine learning, and data analytics, are transforming the industry, offering personalized healthcare and consumer convenience. E-commerce platforms, mobile applications, prescription refills, and two-factor authentication are also driving growth in the B2C segment. Data protection and quality assurance are crucial for consumer trust, while cross-border e-commerce and medical tourism are expanding opportunities for growth. The market for prescription medications, OTC medications, medical supplies, and healthcare products is expected to continue growing, fueled by increasing healthcare expenses, internet penetration, and the need for cost-effective solutions. Table of Contents: 1 Executive Summary 2 Market Landscape 3 Market Sizing 4 Historic Market Size 5 Five Forces Analysis 6 Market Segmentation Product Medications Health/wellness And Nutrition Personal Care And Essentials Type Rx OTC Geography Europe 7 Customer Landscape 8 Geographic Landscape 9 Drivers, Challenges, and Trends 10 Company Landscape 11 Company Analysis 12 Appendix About Technavio Technavio is a leading global technology research and advisory company. Their research and analysis focuses on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions. With over 500 specialized analysts, Technavio's report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio's comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios. Contacts Technavio Research Jesse Maida Media & Marketing Executive US: +1 844 364 1100 UK: +44 203 893 3200 Email: [email protected] Website: SOURCE Technavio WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

100 Deals associated with Cocaine Hydrochloride

External Link

KEGG	Wiki	ATC	Drug Bank
D02182	Cocaine Hydrochloride	S01HA01 S02DA02 N01BC01 R02AD03	DB00907

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Anesthesia	US	Noden Pharma DACStartup	14 Dec 2017

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Cocaine-Related Disorders	Preclinical	US	Biotie Therapies Oy	01 Jun 2008

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT01906346 (CTgov)	Early Phase 1	Cocaine-Related Disorders	9	Placebo+Cocaine (Low Value Alternative Reinforcer)	afzihogpxw(rnbzjnquwk) = imfrxyvktm pmtewufubv (ybpipsibgj, wgbvusdtcd - daofuwgwrc) View more	-	17 May 2019
				Placebo+Cocaine (Medium Value Reinforcer)	afzihogpxw(rnbzjnquwk) = ncvzwqompf pmtewufubv (ybpipsibgj, bnmobjuego - redviusotf) View more
NCT02383043 (CTgov)	Early Phase 1	Cocaine-Related Disorders	18	Cocaine+Sustained Release d-Amphetamine	aeehbtdyrj(dvamkzstrm) = cylszccadx wvevfpbmei (ftejipvcrd, inrlktlesf - kvuzypldme) View more	-	11 Apr 2019
AAN2018	Not Applicable	Acute Ischemic Stroke cocaine use	-	AIS with cocaine use	nmyymwtshh(lyzvssdkiy) = faydgqvurr vaxebyymov (glemljmohb ) View more	-	10 Apr 2018
				AIS without cocaine use	nmyymwtshh(lyzvssdkiy) = mzarsgdbit vaxebyymov (glemljmohb ) View more
ACR2017	Not Applicable	Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis ANCA antibodies \| inflammatory markers \| haematology and biochemistry profiles	14	Cocaine-induced vasculitis	eceomcumgl(ucpaanrxpo) = tojxqeenet qkiqgkqdci (qypfjwwpov ) View more	Negative	06 Nov 2017
				Cocaine	eceomcumgl(ucpaanrxpo) = pofplfvqbh qkiqgkqdci (qypfjwwpov )
NCT00373880 (CTgov)	Phase 2	Cocaine-Related Disorders	26	Placebo+Cocaine (Placebo + 0mg Cocaine)	eretsyclfp(euwmzwedzb) = rplvnybqsv bsqmtwlohi (lsvvtdruwa, rupipzeidt - ymwsatvgzl) View more	-	11 Sep 2017
				Placebo+Cocaine (Placebo + 12mg Cocaine)	eretsyclfp(euwmzwedzb) = oyaapfyamy bsqmtwlohi (lsvvtdruwa, vwchkloxgk - pfjgkfjlpd) View more
NCT01706952 (CTgov)	Phase 4	Chronic sinusitis	45	Cocaine+adrenaline (Cocaine)	awigtzjwuz(ifggtxevek) = doojojzhic loeeeywnjw (rsuhypfdbo, kmnrdnoctg - qkourhoalr) View more	-	03 May 2017
				Cocaine+adrenaline (Adrenaline)	awigtzjwuz(ifggtxevek) = nokrqvlmxg loeeeywnjw (rsuhypfdbo, rvsyajqphv - flnbhlavlu) View more
ASN2016	Not Applicable	Lupus Nephritis ANA + \| Anti-dsDNA antibody \| PR3-ANCA ... View more	-	Cocaine	ytdisstgal(zpndvrlegd) = fhgaldphto ijvgaezkuh (mhpmqtbjmb ) View more	-	15 Nov 2016
ASCO2016	Not Applicable	Hematologic Neoplasms	136	Cocaine positive and HIV positive	nxchpervvq(fqzekzjfef): OR = 0.09 (95% CI, 0.02 - 0.35)	-	20 May 2016
				Cocaine positive and HIV negative
ASN2010	Not Applicable	Vasculitis MPO \| PR3	11	Cocaine users with ANCA positive vasculitis	zpxzpgiebf(upxwkmnblq) = kjpftftxam opzzcikzoy (qmozbsxegr ) View more	Positive	16 Nov 2010
SurvUDI study (IAS2002)	Not Applicable	-	-	Cocaine injection	kfmzgggvgb(fbnlvjzptv) = exsdqyeyvx ugygivisiz (yjgktysycp, 3.6 - 5.0) View more	-	01 Jan 2002

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis